Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 57Thoracic 4Gynecologic 3Sarcoma 2Head & Neck 2Genitourinary 2Dermatologic 2Breast 2Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 11Triple Negative Breast Neoplasms 8Neoplasm Metastasis 6Stomach Neoplasms 5Colorectal Neoplasms 5Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Melanoma 3Prostatic Neoplasms 2Neoplasms 2Multiple Myeloma 2Hematologic Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Colonic Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thrombocytosis 1Small Cell Lung Carcinoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peritoneal Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Mesothelioma, Malignant 1Lymphoma, Non-Hodgkin 1

Interventions

pembrolizumab 18Trastuzumab 7Docetaxel 7Paclitaxel 6Magnetic Resonance Spectroscopy 5Taxes 4Drug Therapy 4Carboplatin 4Specimen Handling 3Psychiatric Rehabilitation 3Polymerase Chain Reaction 3Nivolumab 3Injections 3Fluorouracil 3Fluorodeoxyglucose F18 3Cyclophosphamide 3Cisplatin 3Capecitabine 3Biopsy 3poly ICLC 2fludarabine 2durvalumab 2belinostat 2atezolizumab 2Radiotherapy 2Oxaliplatin 2Leucovorin 2Lapatinib 2Irinotecan 2Interleukin-12 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Esophageal Neoplasms × Leucovorin × Breast × Clear all
NCT05891171 2026-03-31

ARC-25

Arcus Biosciences, Inc.

Phase 1 Active not recruiting
40 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

NuCana plc

Phase 1/2 Terminated
19 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡